ResMed Inc. (RMD)

Over the past six months, ResMed's stock price has experienced pressure, with declines observed over 30 and 90-day periods. The stock has fallen approximately 22% year-to-date in 2026 and about 30% below its 52-week high. Key events impacting the stock include the release of its third-quarter fiscal year 2026 results, the announcement of a CFO retirement and successor appointment, and the declaration of a quarterly cash dividend. In February 2026, ResMed launched its AirTouch F30i Comfort Full Face CPAP mask in the United States.

Demand for ResMed's products and services is generally considered stable and non-discretionary due to the chronic nature of conditions like sleep apnea and COPD. The company's growth is driven by increasing diagnosis rates, expanding awareness among physicians, and broader insurance reimbursement coverage. However, one report noted "typical seasonal softness" in the third quarter of fiscal year 2025.

ResMed, Inc. is a global medical equipment company specializing in cloud-connectable medical devices and software solutions for respiratory conditions, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies industry. Its core business revolves around designing, manufacturing, and distributing products for the treatment of sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD), as well as other respiratory conditions. Major products include CPAP and bilevel machines, masks, and other patient interface products, as well as cloud-connected software platforms like Brightree and MatrixCare. ResMed's revenue is generated from both the upfront sale of hardware and the ongoing sales of replacement masks, supplies, and software-related services.

ResMed has a significant global presence, operating in over 140 countries. The United States is its primary market, contributing approximately 64% of its sales, with international markets accounting for the remaining 36%. Roughly two-thirds of its revenue comes from the Americas, and the balance from other regions, predominantly Europe, Japan, and Australia. The company has manufacturing facilities in Australia, Singapore, France, and the United States.

ResMed maintains a strong brand reputation as a global leader in digital health and medical devices for respiratory disorders. The company is recognized for its innovative solutions that aim to treat and keep people out of the hospital, empowering them to live healthier lives. While no specific negative events directly impacting ResMed's brand reputation in the past year were prominently highlighted, the broader discussion around GLP-1 weight loss drugs has created concern regarding a potential decline in sleep apnea prevalence. ResMed has also been recognized for corporate citizenship and product design in previous years.

Institutional investors hold a significant majority of ResMed's shares, with ownership reported around 69% to 89%. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and State Street Global Advisors, Inc. Individual insider ownership is less than 1% of the company, with Christopher G. Roberts noted as the largest individual shareholder. The general public, including retail investors, owns approximately 30% of the company.